|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM16 |
Gene summary for TRIM16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM16 | Gene ID | 10626 |
| Gene name | tripartite motif containing 16 | |
| Gene Alias | EBBP | |
| Cytomap | 17p12 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | O95361 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10626 | TRIM16 | LZE2T | Human | Esophagus | ESCC | 3.25e-04 | 6.72e-01 | 0.082 |
| 10626 | TRIM16 | LZE4T | Human | Esophagus | ESCC | 1.88e-39 | 1.47e+00 | 0.0811 |
| 10626 | TRIM16 | LZE5T | Human | Esophagus | ESCC | 7.14e-06 | 7.32e-01 | 0.0514 |
| 10626 | TRIM16 | LZE7T | Human | Esophagus | ESCC | 5.67e-16 | 9.03e-01 | 0.0667 |
| 10626 | TRIM16 | LZE8T | Human | Esophagus | ESCC | 1.36e-11 | 3.87e-01 | 0.067 |
| 10626 | TRIM16 | LZE20T | Human | Esophagus | ESCC | 1.22e-04 | 3.25e-01 | 0.0662 |
| 10626 | TRIM16 | LZE21D1 | Human | Esophagus | HGIN | 2.08e-02 | 1.63e-01 | 0.0632 |
| 10626 | TRIM16 | LZE22D1 | Human | Esophagus | HGIN | 1.21e-03 | 2.26e-01 | 0.0595 |
| 10626 | TRIM16 | LZE22T | Human | Esophagus | ESCC | 5.64e-12 | 1.02e+00 | 0.068 |
| 10626 | TRIM16 | LZE24T | Human | Esophagus | ESCC | 4.60e-20 | 7.04e-01 | 0.0596 |
| 10626 | TRIM16 | LZE21T | Human | Esophagus | ESCC | 6.36e-17 | 1.12e+00 | 0.0655 |
| 10626 | TRIM16 | LZE6T | Human | Esophagus | ESCC | 9.98e-03 | 1.39e-01 | 0.0845 |
| 10626 | TRIM16 | P1T-E | Human | Esophagus | ESCC | 9.51e-22 | 8.33e-01 | 0.0875 |
| 10626 | TRIM16 | P2T-E | Human | Esophagus | ESCC | 9.40e-16 | 3.38e-01 | 0.1177 |
| 10626 | TRIM16 | P4T-E | Human | Esophagus | ESCC | 1.36e-67 | 1.72e+00 | 0.1323 |
| 10626 | TRIM16 | P5T-E | Human | Esophagus | ESCC | 3.82e-33 | 7.06e-01 | 0.1327 |
| 10626 | TRIM16 | P8T-E | Human | Esophagus | ESCC | 5.54e-20 | 4.70e-01 | 0.0889 |
| 10626 | TRIM16 | P9T-E | Human | Esophagus | ESCC | 5.71e-41 | 9.04e-01 | 0.1131 |
| 10626 | TRIM16 | P10T-E | Human | Esophagus | ESCC | 9.32e-10 | 2.70e-01 | 0.116 |
| 10626 | TRIM16 | P11T-E | Human | Esophagus | ESCC | 6.55e-12 | 8.91e-01 | 0.1426 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00182057 | Esophagus | HGIN | peptidyl-lysine modification | 88/2587 | 376/18723 | 2.99e-07 | 1.39e-05 | 88 |
| GO:003052220 | Esophagus | HGIN | intracellular receptor signaling pathway | 62/2587 | 265/18723 | 1.63e-05 | 4.50e-04 | 62 |
| GO:00165708 | Esophagus | HGIN | histone modification | 92/2587 | 463/18723 | 1.70e-04 | 3.30e-03 | 92 |
| GO:00064735 | Esophagus | HGIN | protein acetylation | 45/2587 | 201/18723 | 6.17e-04 | 8.58e-03 | 45 |
| GO:00183945 | Esophagus | HGIN | peptidyl-lysine acetylation | 39/2587 | 169/18723 | 7.46e-04 | 9.90e-03 | 39 |
| GO:00435435 | Esophagus | HGIN | protein acylation | 51/2587 | 243/18723 | 1.33e-03 | 1.57e-02 | 51 |
| GO:00439675 | Esophagus | HGIN | histone H4 acetylation | 19/2587 | 67/18723 | 1.39e-03 | 1.63e-02 | 19 |
| GO:004343420 | Esophagus | HGIN | response to peptide hormone | 79/2587 | 414/18723 | 1.60e-03 | 1.79e-02 | 79 |
| GO:00064755 | Esophagus | HGIN | internal protein amino acid acetylation | 36/2587 | 160/18723 | 1.87e-03 | 2.01e-02 | 36 |
| GO:00483844 | Esophagus | HGIN | retinoic acid receptor signaling pathway | 11/2587 | 31/18723 | 2.02e-03 | 2.12e-02 | 11 |
| GO:00183935 | Esophagus | HGIN | internal peptidyl-lysine acetylation | 35/2587 | 158/18723 | 2.82e-03 | 2.75e-02 | 35 |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM16 | SNV | Missense_Mutation | novel | c.1115N>T | p.Ala372Val | p.A372V | O95361 | protein_coding | tolerated(0.13) | benign(0.044) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TRIM16 | SNV | Missense_Mutation | novel | c.1639N>C | p.Asp547His | p.D547H | O95361 | protein_coding | deleterious(0.03) | probably_damaging(0.956) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| TRIM16 | SNV | Missense_Mutation | c.1081G>C | p.Glu361Gln | p.E361Q | O95361 | protein_coding | tolerated(0.07) | possibly_damaging(0.796) | TCGA-EK-A2R9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRIM16 | SNV | Missense_Mutation | novel | c.251C>G | p.Thr84Ser | p.T84S | O95361 | protein_coding | tolerated(0.65) | benign(0.014) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM16 | SNV | Missense_Mutation | rs746816242 | c.946N>A | p.Glu316Lys | p.E316K | O95361 | protein_coding | deleterious(0.02) | benign(0.02) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM16 | SNV | Missense_Mutation | c.1646N>T | p.Gly549Val | p.G549V | O95361 | protein_coding | deleterious(0.01) | probably_damaging(0.933) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM16 | SNV | Missense_Mutation | c.449N>A | p.Cys150Tyr | p.C150Y | O95361 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TRIM16 | SNV | Missense_Mutation | c.907C>A | p.Leu303Met | p.L303M | O95361 | protein_coding | deleterious(0.04) | probably_damaging(0.968) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM16 | SNV | Missense_Mutation | novel | c.29N>A | p.Gly10Glu | p.G10E | O95361 | protein_coding | deleterious_low_confidence(0.04) | benign(0.011) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM16 | SNV | Missense_Mutation | c.121G>A | p.Glu41Lys | p.E41K | O95361 | protein_coding | tolerated(0.15) | benign(0.006) | TCGA-CK-5912-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |